David Gerber, MD, and Steven Vernino, PhD, provide a discussion on Lambert-Eaton Myasthenic Syndrome (LEMS), its association with small cell lung cancer, and the available treatment options.
EP. 1: Defining LEMS
EP. 2: Testing for LEMS
EP. 3: LEMS Case Review
EP. 4: LEMS Diagnosis: Patient Presentation and Testing
EP. 5: Front-line Treatment Options for SCLC
EP. 6: Treatment Options for LEMS
EP. 7: Monitoring Patients with SCLC and LEMS
EP. 8: Case Review: Small Cell Lung Cancer Following LEMS
EP. 9: Clinical Pearls and the Future of LEMS
Benefit of Adjuvant Abemaciclib Increases at 4-Year monarchE Landmark Analysis for Patients With HR+/HER2– High-Risk Early Breast Cancer
Everolimus Plus Adjuvant Endocrine Therapy Fails to Improve iDFS, OS in HR+/HER2- Breast Cancer
Frontline Ribociclib Plus Endocrine Therapy Provides PFS Benefit in Pre/Perimenopausal HR+/HER2- Advanced Breast Cancer
Chemotherapy Followed by Endocrine Therapy Could Increase Cognitive Impairment in Breast Cancer, Irrespective of Menopausal Status
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.